Your NGS report decoded.
Your treatment strategy refined.
A molecular second opinion in oncology. We transform complex genomic sequencing data into clear, actionable clinical recommendations, bridging the gap between laboratory findings and treatment decisions.
Raw genomic data is noise.
Our job is to make it
signal.
Raw NGS Output
Hundreds of variants across DNA, RNA, protein. Annotation thin or absent. Clinical relevance unsorted.
Filter
Strip artifacts, germline noise, low-coverage calls. Retain candidates with somatic confidence.
Prioritize
Rank by oncogenic role, allele frequency, pathway position, and clinical actionability score.
Interpret
Match each driver to FDA labels, guideline rec's, trials, and emerging literature. Tier 1 / 2 / 3.
Decide
Physician-reviewed roadmap: 1L → 2L → 3L+ with anticipated resistance and trial alternatives.
DNA alone misses what changes lives.
Many oncologists order only a DNA-based NGS panel. We integrate DNA · RNA · protein (IHC) · germline, because a single missing layer can hide a Tier IA finding.
Cholangiocarcinoma · 40 yo
A 648-gene DNA panel returned zero actionable variants. On paper, the tumor had no therapeutic targets.
RNA fusion analysis detected an FGFR2-VCL fusion, a Tier IA finding with two FDA-approved therapies (futibatinib, pemigatinib).
DNA panels miss intronic-breakpoint fusions outside probe coverage.
RNA detects the transcript regardless of breakpoint location.
Precision Targeting.
Drivers at the center.
Context
in the periphery.
Treatment as a journey,
not a list of drugs.
Evidence in strata.
So physicians always know how strong the ground is.
Six steps beyond the standard report.
Standard NGS reports list mutations and mention drug matches. We add six layers your treating oncologist can act on immediately.
Variant Tier Classification
Every variant graded Tier IA → IV per current NCCN, MSK OncoKB, and FDA, then re-graded against your tumor type. A mutation that is Tier IA in lung may be Tier II elsewhere. We make that distinction explicit.
Immunotherapy Suitability Score
A quantitative IO score from five parameters: TMB · MSI · PD-L1 · active driver penalty · ultra-low TMB penalty. Positive = IO candidate. Zero or negative = IO not recommended as monotherapy.
Treatment Sequencing 1L → 2L → 3L+
Cancer treatment is a sequence, not a decision. Preferred 1L with alternatives, 2L matched to expected resistance, 3L+ with experimental and trial options, each annotated with ORR, PFS, OS evidence.
Anticipatory Resistance Strategy
A 4-step plan: (1) what to test at progression, (2) which resistance mutations to expect, (3) which next-gen agents address each, (4) which trials to reserve. For FGFR2: V564F, N549K · tinengotinib · lirafugratinib.
Clinical Trial Matching
Independent, real-time matching against ClinicalTrials.gov and institutional databases. Molecular + HLA + geography (Türkiye, Balkans, EU prioritized). NCT, phase, city, and exact eligibility per match.
First-Person Physician Commentary
Every report includes a dedicated commentary written in the first person by Prof. İbrahim Yıldız: a clinical letter your treating oncologist can act on directly, in plain language.
From NGS upload to clinical advisory.
A streamlined, secure process for both referring oncologists and patients seeking molecular second opinions.
Upload your NGS
Send your NGS report (Tempus, FoundationOne, Guardant, Caris, or any panel) via our secure portal with basic clinical context.
Multi-platform analysis
DNA · RNA · protein · IHC integrated. Cross referenced with current NCCN guidelines, FDA approvals, and active clinical trials.
Expert review
Prof. İbrahim Yıldız personally reviews every case, validating tier classifications, treatment recommendations, and trial matches.
Report delivery
Two documents within 48-72 h: the structured IYGAS™ advisory and the physician commentary. Optional video consultation.
Two documents.
One complete picture.
Every consultation produces two complementary reports: a structured English-language molecular advisory and a physician commentary in your preferred language.
IYGAS™ Molecular Advisory
14 SECTIONS- 01 Patient demographics & specimen context
- 02 Executive clinical summary · critical findings
- 03 Genomic & biomarker profile (all platforms)
- 04 VAF & clonality interpretation model
- 05 Auto-tier classification (IA → IV)
- 06 Treatment decision matrix (1L / 2L / 3L+)
- 07 Immunotherapy suitability score
- 08 4-step resistance management strategy
- 09 Pharmacogenomics · dose & toxicity
- 10 Drug interactions vs. planned therapy
- 11 Clinical trial matching framework
- 12 VUS registry with biological context
- 13 Evidence library & literature support
- 14 Physician advisory conclusion + signature
Physician Commentary
MULTILINGUAL- — First-person clinical narrative by Prof. İbrahim Yıldız
- — "Why this finding matters": explained, not just listed
- — "Why I recommend this treatment": with evidence rationale
- — "Why immunotherapy is/isn't appropriate": IO score explained
- — VUS interpretation with biological mechanism
- — Clinical trial recommendations with eligibility context
- — Age/gender-specific considerations (fertility, germline)
- — Available in TR · EN · BG · RO · BA
One clear price. No hidden fees.
A single package: the full written report plus a personal consultation. Every case is reviewed and signed by Prof. İbrahim Yıldız.
A complete fourteen-section written interpretation, plus a 30-minute personal video consultation with Prof. İbrahim Yıldız to walk through the findings.
- 14-section structured IYGAS™ report
- Variant interpretation & therapy matching
- Active clinical trial recommendations
- 30-min video consultation w/ Prof. İbrahim Yıldız
- Referring physician dialogue (optional)
- 60-day follow-up support · EN · TR · BG · RO · BA
One platform
Two ways in
A clinical co-pilot, not a lab printout.
Workflow-integrated reports. EHR-compatible exports. Outcomes data. Direct line to the reviewing oncologist.
Why your doctor sent your report here.
We translate the genomic findings on your report into the treatment options your doctor will discuss with you, in plain language, with privacy protected.
Expert-led. Technology-powered.
NGS Advisory is a boutique molecular oncology advisory, a small, specialized team combining deep clinical experience, cancer genomics expertise, and advanced technology.
Prof. İbrahim Yıldız, MD
Professor of Medical Oncology at Acıbadem Mehmet Ali Aydınlar University, Istanbul. Member of ASCO and ESMO. Author of 133 peer-reviewed publications. Personally reviews and signs every advisory.
Assoc. Prof. Taşcı
Associate Professor specializing in cancer genomics, multi-platform NGS interpretation, and clinical trial matching. Leads the platform integration layer (DNA · RNA · protein · germline).
Genomics Consultant
Our genomics consultant is a specialist in cancer molecular biology with expertise in NGS data interpretation, variant annotation, and molecular pathway analysis. Their role is to ensure every genomic finding (from single nucleotide variants to complex structural rearrangements) is accurately characterized, correctly classified, and placed in the appropriate biological context.
Software Engineer
The architect behind the Ibrahim Yildiz Genomic Advisory System™ (IYGAS), the proprietary platform that structures, formats, scores, and produces our molecular advisory reports. The system integrates multi-platform NGS data, calculates immunotherapy suitability scores, generates tier classifications, and produces publication-quality formatted reports with color coded clinical tables.